Intraperitoneal (IP) therapy with platinum (Pt)-based drugs has shown promising results clinically; however, high locoregional concentration of the drug could lead to adverse side effects. In this study, IP administration was coupled with a folate receptor-targeted (FRT) liposomal system, in an attempt to achieve intracellular delivery of the Pt-based drug carboplatin in order to increase therapeutic efficacy and to minimize toxicity. In vitro and in vivo activity of FRT carboplatin liposomes was compared with the activity of free drug and nontargeted (NT) carboplatin liposomes using FR-overexpressing IGROV-1 ovarian cancer cells as the model. Significant reduction in cell viability was observed with FRT liposomes, which, compared with the free drug, provided an approximately twofold increase in carboplatin potency. The increase in drug potency was correlated with significantly higher cellular accumulation of Pt resulting from FRT liposomal delivery. Further evaluation was conducted in mice bearing intraperitoneally inoculated IGROV-1 ovarian tumor xenografts. A superior survival rate (five out of six animals) was achieved in animals treated with FRT carboplatin liposomes, injected intraperitoneally with a dose of 15 mg/kg and following a schedule of twice-weekly administration for 3 weeks. In contrast, no survivors were observed in the free drug or NT carboplatin liposome groups. The presence of cancer cells in lung and liver tissues was observed in the saline, free carboplatin, and NT carboplatin liposome groups. However, there was no sign of cancer cells or drug-related toxicity detected in tissues from the animals treated with FRT carboplatin liposomes. The results of this study have demonstrated for the first time that the approach of coupling IP administration with FRT liposomal delivery could provide significantly improved therapeutic efficacy of carboplatin in the treatment of metastatic ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282613 | PMC |
| http://dx.doi.org/10.2147/IJN.S26172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacoeconomic Analysis of Treating Gynecological Cancer with Different Regimens Using the Cheapest and Costliest Brand of Drugs Marketed in India.
J Obstet Gynaecol India
December 2024
Research Unit, Mangalore Institute of Oncology, Pumpwell, Mangalore, Karnataka 75002 India.
Article Synopsis
- The study aimed to analyze the cost differences of treating gynaecological cancer in India by comparing the prices of the most and least expensive branded drugs available.
- The researchers conducted a conventional pharmacoeconomic study, assessing both branded drugs and those from Jan Aushadhi stores to determine cost variations and potential savings.
- Findings revealed significant cost disparities, particularly with certain regimens, indicating that cheaper alternatives could lead to substantial savings for patients without sacrificing treatment options.
Fabrication of Biomimetic Hybrid Liposomes via Microfluidic Technology: Homotypic Targeting and Antitumor Efficacy Studies in Glioma Cells.
Int J Nanomedicine
December 2024
Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy.
Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery system using liposomes modified with cell membrane fragments. These modified liposomes can evade the immune system, cross the BBB, and accumulate in tumor tissue through homotypic targeting, thereby delivering drugs like paclitaxel and carboplatin more effectively.
View Article and Find Full Text PDFRapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh.
Hosp Pharm
September 2024
Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Article Synopsis
- Antitumoral drugs (ADs) can trigger hypersensitivity reactions (DHRs), and rapid drug desensitization (RDD) protocols are employed to safely administer these treatments at effective doses.
- The "DESARCh" retrospective study assessed the RDD protocols carried out at an Italian hospital over 11 years, including a detailed 5-step infusion method to reduce DHR incidence for patients with various cancers.
- Out of 66 RDD protocols for 25 female patients, the overall success rate was 81.82%, although carboplatin had a significantly lower success rate compared to other ADs, highlighting the need for further research in this area.
Formulation and Characterization of RBCS Coated Carboplatin Loaded Nano-Liposomal Formulation for Managing Breast Cancer.
Drug Dev Res
December 2024
Department of Pharmaceutics and Industrial Pharmacy, PharmD Program, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt.
Cell membrane-coated Nano-Liposomes (CM-NLPs) offer a promising approach that combines the advantages of both host cells and synthetic nano-liposomes (NLPs). This technique involves coating liposomes with red blood cell (RBC) membranes to enhance their functionality. In this study, novel carboplatin-loaded NLPs (CP-NLPs) were formulated using phospholipids (Soya Phosphatidyl Choline) and cholesterol through the thin-film hydration method, and optimized using a 3 full factorial design.
View Article and Find Full Text PDFEfficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial.
J Natl Cancer Cent
June 2024
The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
Background: The paclitaxel liposome formulation, encapsulating paclitaxel within a phospholipid bilayer, addresses the insolubility of traditional paclitaxel formulations, thereby reducing toxicity without compromising its antitumor efficacy.
Methods: This multicenter, open-label, non-inferiority randomized controlled trial (ChiCTR2000038555) evaluates the efficacy and safety of paclitaxel liposome in comparison to the standard regimen of paclitaxel combined with carboplatin (PLC vs. PC) as first-line therapy in patients with epithelial ovarian cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!